Stuart Therapeutics, Inc. is a Florida-based life sciences company developing a unique synthesized collagen mimetic polypeptide (PolyCol), which acts as a direct reparative to damaged collagen membranes and structures. Its repair mechanism acts rapidly, restoring healthy tissues and protein signaling functions, restoring healthy epithelial and endothelial tissues and reducing inflammation. The company’s first drug candidate, ST-100, is a topical solution for dry eye disease. In animal models, ST-100 completely restored severely damaged corneal tissues to normal, with no inflammation after only 24 hours. The company is developing additional indications for PolyCol, and recently completed animal proof of concept tests confirming positive neuroprotective properties in a mouse glaucoma model. The company has also completed promising in vitro tests in a model duplicating the damage process for dry age-related macular degeneration. We are seeking capital investment of up to $10M.